Improved Efficacy with Response- and MRD-Guided Ibrutinib-Obinutuzumab (IO) Intensification after Ibrutinib-Venetoclax (IV) in First Line Chronic Lymphocytic Leukemia (CLL) Patients: Primary Analysis of the HOVON 158/next STEP Phase 2 Trial
Blood(2024)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined